crossing the
Barrier
NeOnc is the developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions imposed by the body’s Blood-Brain Barrier (BBB). Using NeOnc’s formulations, pharma companies that have limited success with their CNS therapeutics because of current delivery restrictions may be able to provide patients with potentially more effective treatments.
the
Problem
The potential for greater success in treating CNS-based diseases such as Glioblastoma remains limited by the inability to deliver therapeutics directly to the brain.
READ MORE >
our
Solution
Our proprietary approaches and patented technologies deliver new therapies for treating brain cancers as well as facilitating the transport of established or new therapeutics across the blood-brain barrier to improve efficacy for the treatment of diseases in the brain.
READ MORE >
the
Potential
By providing a regulator for tumor cell growth along with a transport mechanism for therapeutics, plan to provide doctors and health-care professionals with a way to deliver better outcomes for their patients.
READ MORE >
LATEST RESEARCH and STUDY
NeOnc maintains an aggressive regimen of research and study into its delivery of therapeutics and formulations to validate and ensure our ability to have an impact on the treatment of CNS-based disease.
April 19, 2024
Study Shows NEO400 Has Therapeutic Effect On UV-Induced Skin Damagen →
December 29, 2023
NEO100 Enhances Entry And Therapeutic Activity Of Chimeric Antigen Receptor T Cells →
